Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases?

References

• Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch. Intern. Med.154(23), 2666–2677 (1994).
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ180(1), 48–58 (2009).
   PubMed Web of Science ®Google Scholar
• Granger RH, Walters JAE, Poole P et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.4, CD001390 (2006).
   Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet349, 1498–1504 (1997).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Antonio Anzueto A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med.176, 532–555 (2007).
   PubMed Web of Science ®Google Scholar
• Murtagh E, Heaney L, Gingle J, Sheperd R et al. Prevalence of obstructive lung disease in a general population sample: the NICECOPD study. Eur. J. Epidemiol.20, 443–453 (2005).
   PubMed Web of Science ®Google Scholar
• Chen Y, Steward P, Dules R, Johansen H, Bryan S, Taylor G. Changing age-pattern of hospitalization of chronic obstructive pulmonary disease in men and women in Canada. Age Ageing34, 373–377 (2005).
   PubMedGoogle Scholar
• Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax61, 189–195 (2006).
   PubMed Web of Science ®Google Scholar
• Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Resp. Med.103, 224–229 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson ML, Neuzil KM, Thompson W et al.The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis.39, 1642–1650 (2004).
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low risk patients with community-acquired pneumonia. N. Engl. J. Med.336, 243–250 (1997).
   PubMed Web of Science ®Google Scholar
• Torres A, Menendez R. Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur. Respir. J.28, 262–263 (2006).
   PubMedGoogle Scholar
• Roson B, Carratala J, Dorca J, Casanova A, Mansera F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin. Infect. Dis.33, 158–165 (2001).
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur. Resp. J.28, 346–351 (2008).
   Web of Science ®Google Scholar
• Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest117(Suppl. 2), 380S–385S (2000).
   Google Scholar
• Saint S, Flaherty KR, Abrahamse P et al. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost–effectiveness of antimicrobial therapy. Clin. Ther.23, 499–512 (2001).
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med.359, 2355–2365 (2008).
   PubMed Web of Science ®Google Scholar
• Ko FW, Ip M, Chan PK, Ng SS, Chau SS, Hui DS. A one year-prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Resp. Med.102, 1109–1116 (2008).
   PubMed Web of Science ®Google Scholar
• Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Can. Fam. Phys.45, 2381–2393 (1999).
   PubMed Web of Science ®Google Scholar
• Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam. Pract.1, 1 (2000).
   PubMedGoogle Scholar
• Cornu C, Yzèbes D, Léophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine19, 4780–4790 (2001).
   PubMed Web of Science ®Google Scholar
• Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine20, 2166–2173 (2002).
   PubMed Web of Science ®Google Scholar
• Dear KB G, Andrews R, Holden J, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev.4, CD000422 (2003).
   Google Scholar
• Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur. J. Epidemiol.19, 353–363 (2004).
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev.3, CD000422 (2007).
   Google Scholar
• Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine22, 927–946 (2004).
   PubMed Web of Science ®Google Scholar
• Smith MD, Sheppard CL, Hogan A et al.; South West Pneumococcus Study Group. Diagnosis of Streptococcus pneumoniae infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection. J. Clin. Microbiol.47, 1046 (2009).
   PubMedGoogle Scholar
• Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med.325, 1453–1460 (1991).
   PubMed Web of Science ®Google Scholar
• Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine22, 3214–3224 (2004).
   PubMed Web of Science ®Google Scholar
• Jackson L, Neuzil M, Yu O et al. Effectiveness of polysaccharide pneumococcal vaccine in older adults. N. Engl. J. Med.348, 1747–1755 (2003).
   PubMed Web of Science ®Google Scholar
• Dominguez A, Salleras L, Fedson D et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case control study. Clin. Infect. Dis.40, 1250–1257 (2005).
   PubMedGoogle Scholar
• Skull SA, Andrews RM, Byrnes GB. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine25, 4631–4640 (2007).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Hospital I et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin. Infect. Dis.43, 860–868 (2006).
   PubMed Web of Science ®Google Scholar
• Landesman SH, Slith P, Shiffman G. Pneumococcal vaccine in elderly patients with COPD. Chest84, 433–435 (1983).
   PubMedGoogle Scholar
• Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ136, 361–365 (1987).
   PubMed Web of Science ®Google Scholar
• Davis A, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. Chest92(22), 204–212 (1987).
   PubMed Web of Science ®Google Scholar
• Musher D, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and olders bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J. Infect. Dis.161, 728–735 (1990).
   PubMed Web of Science ®Google Scholar
• Rubins JB, Puri A K, Loch J et al. Magnitude, duration, quality and function of pneumococcal vaccine responses in elderly adults. J. Infect. Dis.178, 431–440 (1998).
   PubMed Web of Science ®Google Scholar
• Chen M, Hisatomi Y, Furumoto A et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin. Vaccin. Immunol.14(2), 139–145 (2007).
   PubMedGoogle Scholar
• Lai CC, Lee LN, Yu CJ et al.Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease. J. Formos Med. Assoc.3, 196–203 (2007).
   Google Scholar
• Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistance of antibodies to pneumococcal polysaccharide vaccine in the elderly. J. Infect. Dis.176, 1100–1104 (1997).
   PubMed Web of Science ®Google Scholar
• Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease: the effect of ongoing, systemic steroid treatment. Vaccine24, 1408–1412 (2006).
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Musher D, Cetron MS et al. Reduction in functional activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis.29, 281–288 (1999).
   PubMed Web of Science ®Google Scholar
• Schenkein J, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency Vaccine26, 5521–5526 (2008).
   PubMed Web of Science ®Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Ansa X. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine26, 1955–1962 (2008).
   PubMed Web of Science ®Google Scholar
• Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J. Gen. Int. Med.22, 62–67 (2007).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case–control study. Vaccine27, 1504–1510 (2009).
   PubMed Web of Science ®Google Scholar
• Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung diseases. Vaccine17, S91–S93 (1999).
   PubMed Web of Science ®Google Scholar
• Sumitani M, Tochino Y, Kamimori T, Fujiwara H, Fujikawa T. Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients. Int. Med.47, 1189–1197 (2008).
   PubMed Web of Science ®Google Scholar
• Furumoto, Ohkusa Y, Chen M et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine26, 4284–4289 (2008).
   PubMed Web of Science ®Google Scholar
• Musher DM, Rueda-Jaimes AM, Edward A, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin. Infect. Dis.43, 1004–1008 (2006).
   PubMed Web of Science ®Google Scholar
• Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2003. Can. Respir. J.10(Suppl. A), 5A–65A (2003).
   Google Scholar
• Woodhead M, Blasi F, Ewig S. ERS Task Force in Collaboration with ESCMID. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J.26, 1138–1180 (2005).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society. Consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44, S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Eurosurveillance10, 174–178 (2005).
   Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med.348, 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, Fletcher M, Fritzel B, Ciuryla B, Schranz J. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine. Vaccine25, 2420–2427 (2007).
   PubMed Web of Science ®Google Scholar
• Hammit LL, Bruden DL, Butler JC et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal diseases. J. Infect. Dis.193, 1487–1494 (2006).
   PubMedGoogle Scholar
• Grijalva CG, Nuorti P, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time series analysis. Lancet369, 1179–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Haber M, Baskey A, Baughman W et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine25, 5390–5398 (2007).
   PubMed Web of Science ®Google Scholar
• Mooney JD, Weir A, McMenamin J et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect. Dis.8(53), 1–12 (2008).
   PubMedGoogle Scholar
• De Roux A, Schmoele-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis.46, 1015–1023 (2008).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Hachmann M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccine: is hyporesponsiveness an issue? Lancet Infect. Dis.7, 597–606 (2007).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Nahm MH et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.Vaccine25, 4029–4037 (2007).
   PubMed Web of Science ®Google Scholar
• Dransfield MK, Nahm MH, Kan MK et al.Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.180, 499–505 (2009).
   PubMed Web of Science ®Google Scholar
• Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit. Rev. Microbiol.32, 139–153 (2006)
   PubMed Web of Science ®Google Scholar
• Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesion A (PsaA): a review. Clin. Rev. Microbiol.34, 163–173 (2008).
   Google Scholar
• Cao J, Li D, Gong Y et al. Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin. Exp. Immunol.156(1), 52–60 (2009).
   PubMed Web of Science ®Google Scholar